BIGBEAR
PHARMACEUTICAL
Mobocertinib achieves targeted antitumor effects by precisely inhibiting the mutant target to block tumor cell proliferation and survival.
AuthenticGuaranteeFast DeliveryPrivacy The appearance of the Lao Dabear version of Mobocertinib has not only broken the monopoly of high-priced original drugs but has also become a highly a···【More】
Update: 04 Jun,2026Source: BigbearViews: 70
As the first Southeast Asian generic option for the originator drug Mobocertinib, the Laos Dabear version of Mobocertinib brings new hope to patients ···【More】
Update: 04 Jun,2026Source: BigbearViews: 69
The Lao Daewoong version of Mobocertinib is an oral targeted drug for non-small cell lung cancer with EGFR exon 20 insertion mutation. It is a high-qu···【More】
Update: 04 Jun,2026Source: BigbearViews: 69
The price of mobotinib after reimbursement under China's national medical insurance varies depending on the specific circumstances. Choosing the g···【More】
Update: 26 Feb,2026Source: BigbearViews: 108
The specific price of Mobocertinib is currently affected by the purchase channel, regional policies, and medical insurance reimbursement. This drug mu···【More】
Update: 26 Feb,2026Source: BigbearViews: 108
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
